Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VITAL-2: Docetaxel + GVAX in Symptomatic mHRPC
NCT00133224Phase 3Terminated
- Sponsor
- Cell Genesys
- Start
- Jul 2005
- Primary completion
- Aug 2008
- Modality
- Gene Editing, Gene Silencing, Viral Vectors
- Countries
- 10
01
Overview
Phase 3, randomised, open-label trial of Ad.TK in prostate cancer (PCa) (2 arms), sponsored by Cell Genesys. Primary endpoint: Overall Survival. Started Jul 2005; status: terminated.
02
Drugs
Ad.TK
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00133224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00133224.